Skip to main content
Top
Published in: Archives of Virology 2/2019

01-02-2019 | Original Article

Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users

Authors: Maryam Sheikh, Farah Bokharaei-Salim, Seyed Hamidreza Monavari, Angila Ataei-Pirkooh, Maryam Esghaei, Najmeh Moradi, Roghayeh Babaei, Atousa Fakhim, Hossein Keyvani

Published in: Archives of Virology | Issue 2/2019

Login to get access

Abstract

Occult HCV infection (OCI) has been described as the presence of hepatitis C virus (HCV) genomic RNA in hepatocytes and/or peripheral blood mononuclear cell (PBMC) specimens and the lack of HCV genomic RNA and anti-HCV antibodies (Abs) in plasma samples. Injection drug users (IDUs) are the most important high-risk group for infection with blood-borne viruses, particularly HCV. The purpose of this study was to determine the presence of OCI in IDUs. A prospective cross-sectional study of 126 consecutive Iranian IDUs was performed from March 2017 to January 2018. PBMCs were separated from blood samples from the participants, and after extraction of the viral RNA from the plasma and PBMC specimens, HCV RNA was detected in the samples using RT-nested PCR by amplification of the 5′-NTR of HCV. HCV genotyping was carried out using restriction a fragment length polymorphism (RFLP) assay. The viral RNA was amplified using RT-nested PCR with specific primers for the NS5B gene, and the PCR products were sequenced to confirm the results obtained by HCV RNA detection and HCV genotyping. Out of the 126 IDUs studied, 105 (83.3%) were negative for anti-HCV Abs and HCV RNA in plasma samples, whereas HCV RNA was detected in the PBMC samples of six (5.7%) participants, indicating that these individuals had OCI. Moreover, HCV genomic RNA was detected in PBMC samples from five (23.8%) of the 21 IDUs studied who were positive for anti-HCV Abs and negative for HCV genomic RNA in plasma specimens. These IDUs also had OCI. The HCV genotypes in the PBMC samples from the subjects with OCI were determined. Six (54.5%) subjects were infected with HCV subtype 3a, and five (45.5%) were infected with HCV subtype 1a. This study showed that 8.7% of the Iranian IDUs had OCI, and therefore, a study focusing on the diagnosis of OCI in these individuals can be valuable and informative.
Literature
1.
go back to reference Fields B, Knipe D, Howley P (2013) Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia Fields B, Knipe D, Howley P (2013) Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
3.
go back to reference Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M (2016) Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clin Microbiol Infect 22(10):853–861CrossRefPubMed Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M (2016) Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clin Microbiol Infect 22(10):853–861CrossRefPubMed
4.
go back to reference Hellard M, Sacks-Davis R, Gold J (2009) Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49(4):561–573CrossRefPubMed Hellard M, Sacks-Davis R, Gold J (2009) Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49(4):561–573CrossRefPubMed
5.
go back to reference Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G et al (2007) Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 91(2):228–235CrossRefPubMed Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G et al (2007) Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 91(2):228–235CrossRefPubMed
6.
go back to reference Roy E, Alary M, Morissette C, Leclerc P, Boudreau J, Parent R et al (2007) High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Std Aids 18(1):23–27CrossRefPubMed Roy E, Alary M, Morissette C, Leclerc P, Boudreau J, Parent R et al (2007) High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Std Aids 18(1):23–27CrossRefPubMed
7.
go back to reference Daniels D, Grytdal S, Wasley A (2009) Surveillance for acute viral hepatitis—United States, 2007. Morb Mortal Wkly Rep Surveill Summ 58(3):1–27 Daniels D, Grytdal S, Wasley A (2009) Surveillance for acute viral hepatitis—United States, 2007. Morb Mortal Wkly Rep Surveill Summ 58(3):1–27
8.
go back to reference Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM et al (2007) Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 18(5):359–363CrossRefPubMed Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM et al (2007) Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 18(5):359–363CrossRefPubMed
9.
go back to reference Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M (2012) High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province. Southwest Iran. Arch Iran Med. 15(5):271–274PubMed Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M (2012) High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province. Southwest Iran. Arch Iran Med. 15(5):271–274PubMed
10.
go back to reference Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A et al (2013) Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 13(8):e12411CrossRefPubMedPubMedCentral Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A et al (2013) Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 13(8):e12411CrossRefPubMedPubMedCentral
11.
go back to reference Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D et al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791):571–583CrossRefPubMedPubMedCentral Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D et al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791):571–583CrossRefPubMedPubMedCentral
12.
go back to reference Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 161(7):1899–1906CrossRefPubMed Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 161(7):1899–1906CrossRefPubMed
13.
go back to reference Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K et al (2016) Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol 88(11):1960–1966CrossRefPubMed Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K et al (2016) Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol 88(11):1960–1966CrossRefPubMed
14.
go back to reference Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefPubMed Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefPubMed
15.
go back to reference Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78(11):5867–5874CrossRefPubMedPubMedCentral Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78(11):5867–5874CrossRefPubMedPubMedCentral
16.
go back to reference Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefPubMed Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefPubMed
17.
go back to reference Carreño V (2014) Seronegative occult hepatitis C virus infection: Clinical implications. J Clin Virol 61(3):315–320CrossRefPubMed Carreño V (2014) Seronegative occult hepatitis C virus infection: Clinical implications. J Clin Virol 61(3):315–320CrossRefPubMed
18.
go back to reference Rezaee-Zavareh MS, Einollahi B (2014) Treatment of occult hepatitis C virus infection: does it need special attention. Hepat Mon 14(7):e16665PubMedPubMedCentral Rezaee-Zavareh MS, Einollahi B (2014) Treatment of occult hepatitis C virus infection: does it need special attention. Hepat Mon 14(7):e16665PubMedPubMedCentral
19.
go back to reference Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN et al (2011) Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 83(6):989–995CrossRefPubMed Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN et al (2011) Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 83(6):989–995CrossRefPubMed
20.
go back to reference Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefPubMedPubMedCentral Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefPubMedPubMedCentral
21.
22.
go back to reference Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S et al (2014) Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86(9):1499–1506CrossRefPubMed Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S et al (2014) Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86(9):1499–1506CrossRefPubMed
23.
go back to reference Dehghani-Dehej F, Sarvari J, Esghaei M, Hosseini SY, Garshasbi S, Kalantari S, et al (2017) Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of iranian patients with HIV infection. J Med Virol Dehghani-Dehej F, Sarvari J, Esghaei M, Hosseini SY, Garshasbi S, Kalantari S, et al (2017) Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of iranian patients with HIV infection. J Med Virol
24.
go back to reference Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 7(1):7–16CrossRefPubMed Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 7(1):7–16CrossRefPubMed
25.
go back to reference Bokharaei-Salim F, Keyvani H, Salehi-Vaziri M, Sadeghi F, Monavari SH, Mehrnoush L et al (2014) Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNalpha-2a/RBV combination therapy in Azerbaijani patients. Arch Virol 159(11):2893–2899CrossRefPubMed Bokharaei-Salim F, Keyvani H, Salehi-Vaziri M, Sadeghi F, Monavari SH, Mehrnoush L et al (2014) Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNalpha-2a/RBV combination therapy in Azerbaijani patients. Arch Virol 159(11):2893–2899CrossRefPubMed
26.
go back to reference Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1–9CrossRefPubMed Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1–9CrossRefPubMed
27.
go back to reference Telles PR, Bastos FI, Guydish J, Inciardi JA, Surratt HL, Pearl M et al (1997) Risk behavior and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. AIDS 11(Suppl 1):S35–S42PubMed Telles PR, Bastos FI, Guydish J, Inciardi JA, Surratt HL, Pearl M et al (1997) Risk behavior and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. AIDS 11(Suppl 1):S35–S42PubMed
28.
go back to reference Dan M, Rock M, Lilos P, Shany SB (1993) Seroepidemiology of hepatitis B and D virus infection among intravenous drug addicts in Israel. Int J Epidemiol 22(1):140–143CrossRefPubMed Dan M, Rock M, Lilos P, Shany SB (1993) Seroepidemiology of hepatitis B and D virus infection among intravenous drug addicts in Israel. Int J Epidemiol 22(1):140–143CrossRefPubMed
29.
go back to reference Ebeling F (1994) Importance of hepatitis C virus infection in Europe and North America. Curr Stud Hematol Blood Transfus 61:164–181CrossRef Ebeling F (1994) Importance of hepatitis C virus infection in Europe and North America. Curr Stud Hematol Blood Transfus 61:164–181CrossRef
30.
go back to reference Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefPubMed Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefPubMed
31.
go back to reference Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 39(3):284–291CrossRefPubMed Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 39(3):284–291CrossRefPubMed
32.
go back to reference Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefPubMed Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefPubMed
33.
go back to reference Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefPubMed Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefPubMed
34.
go back to reference Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S et al (2017) Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16(4):510–513CrossRefPubMed Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S et al (2017) Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16(4):510–513CrossRefPubMed
35.
go back to reference Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefPubMedPubMedCentral Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefPubMedPubMedCentral
36.
go back to reference Baid-Agrawal S, Berg T (2014) Reply to: “underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients”. J Hepatol 61(5):1185–1186CrossRefPubMed Baid-Agrawal S, Berg T (2014) Reply to: “underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients”. J Hepatol 61(5):1185–1186CrossRefPubMed
37.
go back to reference Castillo I, Martinez-Ara J, Olea T, Bartolome J, Madero R, Hernandez E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefPubMed Castillo I, Martinez-Ara J, Olea T, Bartolome J, Madero R, Hernandez E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefPubMed
38.
go back to reference Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM (2012) Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012:429784PubMedPubMedCentral Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM (2012) Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012:429784PubMedPubMedCentral
39.
go back to reference Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News 226:37–41 Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News 226:37–41
40.
go back to reference De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PloS One 7(8):e43541CrossRefPubMedPubMedCentral De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PloS One 7(8):e43541CrossRefPubMedPubMedCentral
41.
go back to reference Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE (2017) Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol 162(1):63–69CrossRefPubMed Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE (2017) Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol 162(1):63–69CrossRefPubMed
42.
go back to reference Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al (2016) Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59(4):204–210CrossRefPubMed Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al (2016) Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59(4):204–210CrossRefPubMed
43.
go back to reference De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PloS One 4(12):e8128CrossRefPubMedPubMedCentral De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PloS One 4(12):e8128CrossRefPubMedPubMedCentral
44.
go back to reference Sugden PB, Pham TN, Ratnarajah S, Cameron B, Bull R, White PA et al (2013) Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. J Viral Hepat 20(10):725–728CrossRefPubMed Sugden PB, Pham TN, Ratnarajah S, Cameron B, Bull R, White PA et al (2013) Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. J Viral Hepat 20(10):725–728CrossRefPubMed
45.
go back to reference Giannini C, Giannelli F, Zignego AL (2006) Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43(5):1166–1167 (author reply 7–8) CrossRefPubMed Giannini C, Giannelli F, Zignego AL (2006) Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43(5):1166–1167 (author reply 7–8) CrossRefPubMed
46.
go back to reference Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J (2010) No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 23(6):594–601CrossRefPubMed Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J (2010) No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 23(6):594–601CrossRefPubMed
47.
go back to reference Richiardi L, De Marco L, Gillio-Tos A, Merletti F, Fiano V, Palli D et al (2010) Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol 34(6):709–712CrossRefPubMed Richiardi L, De Marco L, Gillio-Tos A, Merletti F, Fiano V, Palli D et al (2010) Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol 34(6):709–712CrossRefPubMed
48.
go back to reference Pisaturo M, Guastafierro S, Filippini P, Tonziello G, Sica A, Di Martino F et al (2013) Absence of occult HCV infection in patients experiencing an immunodepression condition. Infez Med 21(4):296–301PubMed Pisaturo M, Guastafierro S, Filippini P, Tonziello G, Sica A, Di Martino F et al (2013) Absence of occult HCV infection in patients experiencing an immunodepression condition. Infez Med 21(4):296–301PubMed
49.
go back to reference Welker MW, Zeuzem S (2009) Occult hepatitis C: how convincing are the current data? Hepatology 49(2):665–675CrossRefPubMed Welker MW, Zeuzem S (2009) Occult hepatitis C: how convincing are the current data? Hepatology 49(2):665–675CrossRefPubMed
50.
go back to reference Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M et al (2015) Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol 4(4):116–120PubMedPubMedCentral Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M et al (2015) Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol 4(4):116–120PubMedPubMedCentral
51.
go back to reference Telfer P, Devereux H, Savage K, Scott F, Dhillon A, Dusheiko G et al (1995) Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 74(5):1259–1264CrossRefPubMed Telfer P, Devereux H, Savage K, Scott F, Dhillon A, Dusheiko G et al (1995) Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 74(5):1259–1264CrossRefPubMed
52.
go back to reference Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84CrossRefPubMed Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84CrossRefPubMed
53.
go back to reference Freitas SZ, Teles SA, Lorenzo PC, Puga MAM, Tanaka TSO, Thomaz DY et al (2014) HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the midwest region of Brazil. Rev Inst Med Trop São Paulo 56(6):517–524CrossRefPubMedPubMedCentral Freitas SZ, Teles SA, Lorenzo PC, Puga MAM, Tanaka TSO, Thomaz DY et al (2014) HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the midwest region of Brazil. Rev Inst Med Trop São Paulo 56(6):517–524CrossRefPubMedPubMedCentral
54.
go back to reference Weber R, Ruppik M, Rickenbach M, Spörri A, Furrer H, Battegay M et al (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 14(4):195–207CrossRefPubMed Weber R, Ruppik M, Rickenbach M, Spörri A, Furrer H, Battegay M et al (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 14(4):195–207CrossRefPubMed
55.
go back to reference Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF et al (2014) Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PloS One 9(4):e94791CrossRefPubMedPubMedCentral Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF et al (2014) Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PloS One 9(4):e94791CrossRefPubMedPubMedCentral
56.
go back to reference Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W et al (2013) Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PloS One 8(12):e82598CrossRefPubMedPubMedCentral Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W et al (2013) Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PloS One 8(12):e82598CrossRefPubMedPubMedCentral
57.
go back to reference Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M (2014) Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 20(19):5897–5902CrossRefPubMedPubMedCentral Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M (2014) Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 20(19):5897–5902CrossRefPubMedPubMedCentral
58.
go back to reference Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Jalali F (2011) Genotypic analysis of hepatitis C virus in khuzestan province, southwestern iran. Middle East J Dig Dis 3(2):126–130PubMedPubMedCentral Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Jalali F (2011) Genotypic analysis of hepatitis C virus in khuzestan province, southwestern iran. Middle East J Dig Dis 3(2):126–130PubMedPubMedCentral
59.
go back to reference Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F et al (2012) Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 157(10):1959–1965CrossRefPubMed Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F et al (2012) Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 157(10):1959–1965CrossRefPubMed
60.
go back to reference Bokharaei Salim F, Keyvani H, Amiri A, Jahanbakhsh Sefidi F, Shakeri R, Zamani F (2010) Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol 16(16):2005–2009CrossRefPubMed Bokharaei Salim F, Keyvani H, Amiri A, Jahanbakhsh Sefidi F, Shakeri R, Zamani F (2010) Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol 16(16):2005–2009CrossRefPubMed
61.
go back to reference Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV–coinfected persons. J Infect Dis 192(2):258–265CrossRefPubMed Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV–coinfected persons. J Infect Dis 192(2):258–265CrossRefPubMed
62.
go back to reference Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001) Treatment of hepatitis C infection in injection drug users. Hepatology 34(1):188–193CrossRefPubMed Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001) Treatment of hepatitis C infection in injection drug users. Hepatology 34(1):188–193CrossRefPubMed
Metadata
Title
Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users
Authors
Maryam Sheikh
Farah Bokharaei-Salim
Seyed Hamidreza Monavari
Angila Ataei-Pirkooh
Maryam Esghaei
Najmeh Moradi
Roghayeh Babaei
Atousa Fakhim
Hossein Keyvani
Publication date
01-02-2019
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2019
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-4066-5

Other articles of this Issue 2/2019

Archives of Virology 2/2019 Go to the issue